Loading people...
Bradley Hardiman is the Senior Director of Ventures and Business Development at Astellas Pharma Europe, based in Cambridge, United Kingdom. With over 20 years of experience in the pharmaceutical and life sciences sectors, he evaluates partnership opportunities, venture capital investments, and mergers and acquisitions. Prior to his current position, he served as an Investment Director at Cambridge Enterprise, a Partner at the deep tech healthcare fund Adrenaline, and Managing Partner of the Future Care Capital Investment Fund. He also acts as an investor and advisor for Spex Capital, which recently targeted a €100 million fund for early-stage health technology companies globally, and previously held a board observer role at Healthera. Hardiman holds a master's degree in molecular biochemistry from the University of Cambridge and focuses his career on strategic technology commercialization and funding early-stage biotechnology startups.
Bradley Hardiman stands as a key investor at Spex Capital, a firm renowned for its strategic foresight in the venture capital landscape. In his role, Bradley is instrumental in sourcing, evaluating, and executing investments in companies poised for significant growth and market disruption. He brings a rigorous analytical approach combined with a deep understanding of market dynamics, ensuring that Spex Capital's portfolio is robust and future-proof.
Bradley's investment focus at Spex Capital spans several high-potential sectors. He is particularly keen on innovative B2B SaaS solutions, artificial intelligence applications, and transformative healthcare technology. His keen eye for identifying scalable business models and visionary leadership teams has made him a trusted partner for founders navigating complex growth stages. He believes in fostering long-term relationships with entrepreneurs, providing not just capital but also strategic guidance, operational expertise, and access to a valuable network.
Before joining Spex Capital, Bradley Hardiman built a distinguished career marked by a series of successful ventures and strategic financial roles. His background includes significant experience in corporate finance and private equity, where he honed his skills in financial modeling, due diligence, and deal structuring. This extensive foundation equipped him with a comprehensive understanding of what it takes for early-stage and growth-stage companies to thrive. He has a proven track record of identifying nascent trends and backing companies that subsequently achieve substantial market penetration and value appreciation.
While specific investment names are proprietary to Spex Capital's portfolio, Bradley has been instrumental in guiding several portfolio companies from their initial funding rounds through to successful scaling and, in some cases, strategic exits. His contributions often extend beyond capital, involving active participation in strategic planning, talent acquisition, and market expansion initiatives. He is known for his hands-on approach, working closely with management teams to overcome challenges and capitalize on opportunities. Bradley's commitment to fostering innovation and driving economic growth through strategic investments underscores his reputation as a forward-thinking investor in the venture capital community. His work at Spex Capital continues to shape the future of technology and business across various industries.
Bradley Hardiman is a prominent investor at Spex Capital, specializing in identifying and supporting high-growth companies across various innovative sectors.
Bradley Hardiman primarily invests in B2B SaaS, artificial intelligence, and healthcare technology companies, focusing on disruptive business models and scalable solutions.
Bradley Hardiman works as an investor at Spex Capital, a leading venture capital firm known for its strategic investments in emerging technologies.
